OVERVIEW

Restrictive Cardiomyopathies Series: Advanced Heart Failure Therapies in ATTR Cardiac Amyloidosis is organized by American College of Cardiology (ACC).

Released Date: Nov 05, 2019
Expiration Date: Nov 05, 2020

Accreditation:
Physicians
• The American College of Cardiology Foundation (ACCF) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
• The ACCF designates this enduring material for a maximum of up to .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

MOC:
• Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Description:
This activity was planned with a goal of improving your knowledge of the advanced heart failure treatment options available for patients with transthyretin (ATTR) cardiac amyloidosis.

Learner Objectives:
Upon completion of this program, you should be able to:
• Define the role of advanced heart failure therapies for advanced transthyretin (ATTR) cardiac amyloidosis.
• Describe outcomes of heart transplantation in ATTR cardiac amyloidosis.
• Discuss indications for current liver transplant in patients undergoing heart transplant.